Real-World Evaluation of Ofatumumab vs Ocrelizumab

B-cell-depleting therapy represents a primary cornerstone in the management of relapsing multiple sclerosis. Clinicians frequently evaluate ofatumumab vs ocrelizumab when choosing high-efficacy disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS). Both monoclonal antibodies target the CD20 surface antigen present on pre-B and mature B lymphocytes. Consequently, both agents induce rapid B-cell cytolysis and suppress acute central nervous system inflammation. However, critical differences exist regarding their routes of administration, dosing intervals, and molecular structures.

Ocrelizumab is a humanized monoclonal antibody administered via intravenous infusion every six months in specialized clinics. In contrast, ofatumumab is a fully human antibody delivered via monthly subcutaneous self-injections using an autopen. Although both medications demonstrated robust efficacy in pivotal phase 3 trials against active comparators, direct head-to-head randomized trials remain absent. Clinicians therefore rely on real-world observational data to guide therapeutic selection. A landmark nationwide study from the Danish Multiple Sclerosis Registry now provides comparative insights into clinical and radiological outcomes. This extensive cohort addresses key questions regarding relapse frequency, disability worsening, and subclinical lesion activity in routine neurological practice.

Study Methodology and Propensity Score Weighting

To evaluate real-world comparative effectiveness, Danish researchers conducted a nationwide observational cohort investigation. They analyzed prospective data recorded in the Danish Multiple Sclerosis Registry between January 2022 and November 2025. The investigators identified 1,870 eligible adult patients with RRMS who initiated either ofatumumab or ocrelizumab. Specifically, 1,385 patients initiated subcutaneous ofatumumab, whereas 485 commenced intravenous ocrelizumab. Additionally, baseline demographics showed a mean age of approximately 41 years in both groups, alongside a characteristic female predominance.

Observational studies frequently encounter confounding by indication because clinicians prescribe specific drugs based on baseline severity. Therefore, researchers employed inverse probability of treatment weighting based on propensity scores to balance baseline prognostic factors. This statistical approach adjusted for key covariates, including patient age, sex, baseline expanded disability status scale scores, prior therapies, and recent relapses. The investigators utilized an intention-to-treat framework to preserve original cohort allocation and prevent bias. Furthermore, they conducted per-protocol sensitivity analyses to verify the consistency of findings over extended follow-up intervals.

Comparative Analysis of Annualized Relapse Rates

The primary clinical endpoint evaluated the annualized relapse rate ratio alongside time to the first on-treatment relapse. Notably, the intention-to-treat analysis revealed exceptionally low absolute relapse rates across both therapeutic cohorts during routine clinical care. Specifically, patients receiving ofatumumab experienced a mean annualized relapse rate of 0.05. In comparison, patients receiving ocrelizumab exhibited a mean annualized relapse rate of 0.03. Consequently, the resulting adjusted rate ratio was 1.65, demonstrating a statistically significant difference between the two anti-CD20 agents.

Nevertheless, when investigators analyzed the time to first relapse, the hazard ratio was 1.50 with a confidence interval crossing unity. Thus, the time to first relapse did not reach statistical significance between the cohorts. The median follow-up duration was 2.0 years for ofatumumab and 2.5 years for ocrelizumab. While ofatumumab demonstrated a mathematically higher rate ratio, both cohorts maintained profound inflammatory suppression. In practical terms, an annualized relapse rate of 0.05 equates to merely one clinical relapse every twenty years. Therefore, clinicians must interpret this minor statistical difference within the broader context of overall therapeutic success.

Disability Progression and Neuroimaging Outcomes

Beyond overt relapses, controlling permanent disability represents the definitive benchmark of modern multiple sclerosis care. The Danish study assessed secondary endpoints, including 24-week confirmed disability worsening and progression independent of relapse activity. In the weighted intention-to-treat population, ofatumumab demonstrated no significant difference in confirmed disability worsening compared with ocrelizumab, yielding a hazard ratio of 0.83. Similarly, progression independent of relapse activity revealed a hazard ratio of 0.78, indicating equivalent protection against insidious neurodegeneration.

Furthermore, neuroimaging surveillance reinforced these clinical observations across both treatment cohorts. Serial brain magnetic resonance imaging scans showed no statistically significant divergence in new or enlarging T2 lesion activity. Specifically, the hazard ratio for brain MRI lesion activity stood at 1.72 with a confidence interval spanning from 0.95 to 3.13. Additionally, per-protocol analyses confirmed identical patterns across all radiological and functional parameters. Because disability accumulation dictates long-term patient autonomy, the equivalence in disability worsening provides profound reassurance to neurologists and patients alike. Both agents successfully mitigated central nervous system tissue damage and slowed chronic disease advancement.

Clinical Significance and Real-World Nuances

Although the study demonstrated a statistical difference in annualized relapse rates, clinicians must weigh clinical relevance against pure mathematical significance. The authors specifically noted that both anti-CD20 therapies achieved exceptional disease control in real-world clinical environments. In fact, the marginal difference of 0.02 relapses per year represents an exceedingly narrow clinical variance. In daily medical practice, such minimal divergence rarely justifies switching a stable patient between these monoclonal antibody therapies. Instead, practical factors often exert a greater influence on therapeutic decision-making.

Route of administration remains a fundamental determinant of treatment selection and patient adherence. Intravenous ocrelizumab mandates dedicated infusion suite visits, pre-medication with antihistamines and corticosteroids, and clinical monitoring twice annually. In contrast, subcutaneous ofatumumab offers autonomous at-home administration, eliminating travel burdens and clinical facility utilization. However, self-administered monthly injections require consistent patient adherence, cold-chain transport integrity, and proper disposal of biological sharps. Additionally, clinicians must monitor immunoglobulin levels over time because prolonged B-cell depletion poses potential infection risks.

Tailoring Anti-CD20 Selection for Indian Practice

In the Indian healthcare landscape, neurologists face distinctive logistical, economic, and geographic considerations when selecting disease-modifying therapies for multiple sclerosis. Access to tertiary infusion suites varies widely between urban healthcare hubs and remote rural regions. Consequently, subcutaneous ofatumumab provides a convenient avenue for individuals living far from advanced medical centers. Nevertheless, maintaining an uninterrupted cold chain at home during severe summer temperatures poses substantial logistical hurdles across various Indian regions. Clinicians must therefore ensure that patients possess reliable refrigeration before prescribing self-administered biologics.

Furthermore, pre-treatment screening assumes paramount importance prior to initiating any B-cell-depleting regimen in endemic regions. Clinicians must systematically screen for latent tuberculosis, hepatitis B virus, and common opportunistic infections. In addition, periodic monitoring of absolute neutrophil counts and serum immunoglobulin levels is essential to prevent severe infectious complications. Clinicians should also discuss family planning and vaccination schedules with reproductive-age patients before commencing therapy. Ultimately, aligning therapeutic mechanisms with patient lifestyle, financial viability, and clinical infrastructure optimizes long-term neurological outcomes effectively.

Frequently Asked Questions

Did ofatumumab show worse disability outcomes than ocrelizumab?

No, ofatumumab demonstrated equivalent disability outcomes compared with ocrelizumab. The Danish registry study revealed no statistically significant differences in 24-week confirmed disability worsening or progression independent of relapse activity between both cohorts. Both therapies provided robust, comparable protection against sustained functional decline and neurological deterioration in relapsing-remitting multiple sclerosis.

Why did the study find a higher relapse rate ratio for ofatumumab?

The study observed an annualized relapse rate of 0.05 for ofatumumab versus 0.03 for ocrelizumab, yielding a rate ratio of 1.65. However, both absolute relapse rates were exceptionally low. Observational nuances, slight differences in reporting, or residual indication bias likely contributed, but the absolute difference remains clinically marginal.

How should clinicians decide between subcutaneous and intravenous anti-CD20 therapy?

Clinicians should tailor the decision to individual patient preferences, geographical accessibility, and treatment adherence capabilities. Subcutaneous ofatumumab offers autonomous at-home administration without infusion clinic visits, requiring dependable refrigeration. Conversely, intravenous ocrelizumab guarantees semi-annual adherence under direct medical supervision in clinical infusion centers, which minimizes patient self-injection anxiety.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. El Mahdaoui S et al. Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Nationwide Cohort Study. Neurology. 2026 Oct 27. doi: 10.1212/WNL.0000000000218545. PMID: 42832743.


2. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234.


3. Hauser SL, Cross AH, Winthrop K, et al. Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med. 2020;383(6):546-557.